SAN DIEGO, Sept. 15, 2011 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX) announced today that the Company has completed the enrollment of the first of two planned Phase 3 trials of tedizolid phosphate (formerly known as torezolid phosphate) in the study of acute bacterial skin and skin structure infections (ABSSSI). The pivotal Phase 3 trial, designated TR701-112, examined the efficacy and safety of a six day course of oral tedizolid phosphate therapy versus 10 days of oral therapy with linezolid (Zyvox®) in 667 patients recruited across sites in North and South America and Europe. Trius plans to start its second Phase 3 trial of tedizolid phosphate in ABSSSI, designated TR701-113, for its intravenous (IV) to oral transition therapy later this year.
